scholarly journals Medium-Chain Triglycerides Lower Blood Lipids and Body Weight in Streptozotocin-Induced Type 2 Diabetes Rats

Nutrients ◽  
2018 ◽  
Vol 10 (8) ◽  
pp. 963 ◽  
Author(s):  
Ming-Hua Sung ◽  
Fang-Hsuean Liao ◽  
Yi-Wen Chien

Medium-chain triglycerides (MCTs) are distinguished from other triglycerides in that each fat molecule consists of 6 to 12 carbons in length. MCTs and long-chain triglycerides (LCTs) are absorbed and utilized in different ways. The aim of this study was to assess the effects of replacing soybean oil with MCT oil, in a low- or high-fat diet, on lipid metabolism in rats with streptozotocin-induced type 2 diabetes mellitus (T2DM). There were, thirty-two T2DM Sprague-Dawley rats divided into low-fat-soybean oil (LS), low-fat-MCT oil (LM), high-fat-soybean oil (HS), and high-fat-MCT oil (HM) groups. After 8 weeks, blood sugar, serum lipids, liver lipids, and enzyme activities related to lipid metabolism were measured. Under a high-fat diet condition, replacement of soybean oil with MCT oil lowered serum low-density lipoprotein cholesterol (LDL-C), non-esterified fatty acids, and liver total cholesterol; whilst it increased serum high-density lipoprotein cholesterol (HDL-C) and the HDL-C/LDL-C ratio. A low-fat diet with MCT oil resulted in lower body weight and reproductive white adipose tissues compared to the HS groups, and higher hepatic acyl-CoA oxidase activities (the key enzyme in the peroxisomal beta-oxidation) compared to the LS group in T2DM rats. In conclusion, MCTs showed more protective effects on cardiovascular health in T2DM rats fed a high-fat diet, by improving serum lipid profiles and reducing hepatic total cholesterol.

2019 ◽  
Vol 10 (9) ◽  
pp. 5804-5815 ◽  
Author(s):  
Fenfen Yan ◽  
Na Li ◽  
Jialu Shi ◽  
Huizhen Li ◽  
Yingxue Yue ◽  
...  

Lactobacillus acidophilus alleviates type 2 diabetes induced by a high fat diet and streptozotocin (STZ) injection by regulating gut microbiota, hepatic glucose and lipid metabolism in mice.


2017 ◽  
Vol 8 (2) ◽  
pp. 243-255 ◽  
Author(s):  
S. Singh ◽  
R.K. Sharma ◽  
S. Malhotra ◽  
R. Pothuraju ◽  
U.K. Shandilya

Restoration of dysbiosed gut microbiota through probiotic may have profound effect on type 2 diabetes. In the present study, rats were fed high fat diet (HFD) for 3 weeks and injected with low dose streptozotocin to induce type 2 diabetes. Diabetic rats were then fed Lactobacillus rhamnosus NCDC 17 and L. rhamnosus GG with HFD for six weeks. L. rhamnosus NCDC 17 improved oral glucose tolerance test, biochemical parameters (fasting blood glucose, plasma insulin, glycosylated haemoglobin, free fatty acids, triglycerides, total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol), oxidative stress (thiobarbituric acid reactive substance and activities of catalase, superoxide dismutase and glutathione peroxidase in blood and liver), bifidobacteria and lactobacilli in cecum, expression of glucagon like peptide-1 producing genes in cecum, and adiponection in epididymal fat, while decreased propionate proportions (%) in caecum, and expression of tumour necrosis factor-α and interlukin-6 in epididymal fat of diabetic rats as compared to diabetes control group. These findings offered a base for the use of L. rhamnosus NCDC 17 for the improvement and early treatment of type 2 diabetes.


2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Yajing Li ◽  
Minli Chen ◽  
Hongzhuan Xuan ◽  
Fuliang Hu

The present study investigates the encapsulated propolis on blood glycemic control, lipid metabolism, and insulin resistance in type 2 diabetes mellitus (T2DM) rats. The animal characteristics and biological assays of body weight, fasting blood glucose (FBG), fasting serum insulin (FINS), insulin act index (IAI), triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured and euglycemic hyperinsulinemic glucose clamp technique were used to determine these effects. Our findings show that oral administration of encapsulated propolis can significantly inhibit the increasing of FBG and TG in T2DM rats and can improve IAI and M value in euglycemic hyperinsulinemic clamp experiment. There was no significant effects on body weight, TC, HDL-C, and LDL-C in T2DM rats treated with encapsulated propolis. In conclusion, the results indicate that encapsulated propolis can control blood glucose, modulate lipid metabolism, and improve the insulin sensitivity in T2DM rats.


Author(s):  
Sarita Mulkalwar ◽  
Tanya Gupta ◽  
Vishwanath Kulkarni ◽  
A. V. Tilak ◽  
B. T. Rane ◽  
...  

Background: As of 2018, 2.1 billion people nearly 30% of the world’s population are either obese or overweight. Worldwide obesity has nearly tripled since 1975. It is an emerging health problem with major adverse effects on health. It is a risk factor for many chronic diseases but is best known for its role in metabolic syndrome, which can lead to type 2 diabetes mellitus as well as cardiovascular diseases. Anti-obesity drugs are available but have many side effects. Voglibose, an antidiabetic drug, is an alpha glucosidase inhibitor which shows promising results in the reduction of body weight with minimal side effects.Methods: Voglibose (7 mg/kg) was administered to rats fed with normal laboratory chows and high fat diet to see its effect on body weight, body mass index, abdominal and thoracic circumference, and lipid profile at the end of 12 weeks.Results: Administration of voglibose significantly reduced food consumption, feed efficiency and increase in body weight induced by high fat diet in rats. Rats fed on normal diet also showed reductions in the same parameters, suggesting its weight lowering effect. Reductions in the anthropometric measurements, hypolipidemic effects and glucose lowering effects were also observed.Conclusions: Voglibose prevented high fat diet-induced obesity and improvement in metabolic profile, which ultimately has systemic effects on body weight in rats. Further studies are needed to see its potential therapeutic use in obese patients with type 2 diabetes mellitus, and related complications.


2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Eun Young Park ◽  
Eung Hwi Kim ◽  
Mi Hwi Kim ◽  
Young Wan Seo ◽  
Jung Im Lee ◽  
...  

Ecklonia cava (E. cava)is a brown alga that has beneficial effects in models of type 1 and type 2 diabetes. However, the effects ofE. cavaextracts on diet-induced obesity and type 2 diabetes have not been specifically examined. We investigated the effects ofE. cavaon body weight, fat content, and hyperglycemia in high-fat diet- (HFD) induced obese mice and sought the mechanisms involved. C57BL/6 male mice were fed a HFD (60% fat) diet or normal chow. After 3 weeks, the HFD diet group was given extracts (200 mg/kg) ofE. cavaharvested from Jeju (CA) or Gijang (G-CA), Korea or PBS by oral intubation for 8 weeks. Body weights were measured weekly. Blood glucose and glucose tolerance were measured at 7 weeks, and fat pad content and mRNA expression of adipogenic genes and inflammatory cytokines were measured after 8 weeks of treatment. G-CA was effective in reducing body weight gain, body fat, and hyperglycemia and improving glucose tolerance as compared with PBS-HFD mice. The mRNA expression of adipogenic genes was increased, and mRNA expression of inflammatory cytokines and macrophage marker gene was decreased in G-CA-treated obese mice. We suggest that G-CA reduces obesity and glucose levels by anti-inflammatory actions and improvement of lipid metabolism.


2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Jesse Rentz ◽  
Jordan Winberg ◽  
Walter Swardfager ◽  
Jane Mitchell

Abstract The skeleton has been characterized as an endocrine organ, demonstrating a capacity to modulate cognition, mood and energy homeostasis (1,2). These endocrine actions of the skeleton have been attributed to the osteoblast-derived peptide osteocalcin. In mice, uncarboxylated osteocalcin (ucOCN) decreased the acquisition of type 2 diabetes mellitus (T2DM) and ameliorated depressive- and anxiety-like behaviours (1,2). Clinically, T2DM patients present with reduced serum osteocalcin levels and approximately 1 in 4 also suffer from co-morbid depression (3,4). The cognitive and metabolic benefits of ucOCN are similar to the beneficial effects of exercise that is recommended in treatment of both depression and T2DM. Here we compared the effects of ucOCN or exercise in female C57-BL/6J mice under two different metabolic conditions. Mice were fed either a high-fat diet (60% calories from fat) to induce T2DM or a control diet (10% calories from fat). Groups of mice were either sedentary or exercised daily by 30 min treadmill running for two months, with or without daily administration of ucOCN (30 ng/g/day). Mice with T2DM displayed depressive behaviours marked by a higher immobile time in tail suspension tests compared to control mice (97±25 n=11 vs 207±9.0 s n=12; t21=4.21, P=0.0004). Exercise and osteocalcin both improved depressive behaviour (137±8 n=12; t22=5.85, P<0.0001 & 127±15 s n=12; t22=4.46, P=0.0002). Anxiety, measured by the elevated-plus maze revealed the mice with T2DM displayed increased anxiety spending less time in the open arms and had a lower ratio of open to closed arm entries than the control group (0.37±0.03 n=10 vs 0.21±0.032 n=11; t19=3.56, P=0.0021). Neither exercise nor osteocalcin improved anxiety in the T2DM mice. The puzzle box test revealed the negative effects of the high-fat diet in problem solving and memory, where the sedentary mice displayed greater latencies to solve each task compared to control mice. Exercised and mice receiving osteocalcin displayed performances comparable to that of the control group. Under normal metabolic conditions (low fat diet), neither osteocalcin nor exercise altered responses in any of the behavioural tests. Together, these results: 1. The effects of osteocalcin on behaviour and cognition are comparable to that of the effects of exercise in female mice with T2DM; 2. Behaviour and cognition did not improve from exercise or osteocalcin in female mice on a low-fat diet. References: (1) Ferron et al., Bone. 2012 Feb;50(2):568–575. (2) Oury et al., Cell. 2013 Sep 26:155(1):228–241. (3) Liu et al., Horm Metab Res. 2015 Oct;47(11):813–9. (4) Khaledi et al., Acta Diabetol. 2019 June;56(6):631–650.


Author(s):  
ASHUTOSH KUMAR YADAV ◽  
REETU ◽  
ARUN GARG

Objective: India is the “diabetes capital of the world” with 62.4 million Indians having type 2 diabetes in 2011. A major risk factor for insulin resistance is obesity, which is generally caused by regular physical inactivity and high-fat diet (HFD). Obesity and diabetes are closely related to each other as about 80% of diabetics are obese. Obesity is a common finding in type 2 diabetes. The objective of the study was to investigate the antidiabetic effects of [10]-gingerol in streptozotocin (STZ)- and HFD-induced diabetic rats. Methods: Wistar rats were used for the study. Animals were divided into six groups. The six groups in this study were, Group I (normal control), Group II (diabetic control), Group III (glibenclamide at 5 mg/kg p.o.), Group IV (orlistat at 60 mg/kg p.o.), Group V ([10]-gingerol at 15 mg/kg p.o.), and Group VI [10]-gingerol (30 mg/kg p.o.), respectively. The antidiabetic activity was assessed using blood glucose level, body weight, and various biochemical parameters such as serum total cholesterol (TC) level, triglyceride (TG) level, high-density lipoproteins (HDLs), total protein (TP), serum alanine transaminase, and aspartate aminotransferase (serum glutamic-oxaloacetic transaminase), respectively. Results: [10]-gingerol exhibited an antidiabetic effect by significantly decreased the level of blood glucose, body weight, TC, TG, TP, and increase HDL. The results of the study demonstrated that the treatment with [10]-gingerol significantly (p<0.05) and dose dependently prevented STZ- and HFD-induced diabetic rats. Conclusions: The findings of the study suggest that [10]-gingerol possesses potential antidiabetic activity as it lowers serum glucose level.


Sign in / Sign up

Export Citation Format

Share Document